bluebird bio
BLUE
BLUE was delisted on the 30th of May, 2025.
241 hedge funds and large institutions have $5.87B invested in bluebird bio in 2019 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 81 increasing their positions, 78 reducing their positions, and 54 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
3% more ownership
Funds ownership: 112.95% → 115.95% (+3%)
4% more repeat investments, than reductions
Existing positions increased: 81 | Existing positions reduced: 78
12% less funds holding
Funds holding: 273 → 241 (-32)
21% less call options, than puts
Call options by funds: $81.7M | Put options by funds: $103M
26% less capital invested
Capital invested by funds: $7.92B → $5.87B (-$2.05B)
56% less first-time investments, than exits
New positions opened: 24 | Existing positions closed: 54
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Sands Capital Management
Arlington,
Virginia
|
+$126M |
| 2 |
Victory Capital Management
San Antonio,
Texas
|
+$112M |
| 3 |
Capital World Investors
Los Angeles,
California
|
+$93.2M |
| 4 |
Capital International Investors
Los Angeles,
California
|
+$41.4M |
| 5 |
CII
Capital International Inc
Los Angeles,
California
|
+$39.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$90.5M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$53.8M |
| 3 |
First Trust Advisors
Wheaton,
Illinois
|
-$47.6M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$28.5M |
| 5 |
Goldman Sachs
New York
|
-$25.8M |
BLUE Hedge Fund Activity: Q3 2019 in Review
241 of the 4,574 institutional investors tracked by Wall St. Rank reported a position in bluebird bio (BLUE) for Q3 2019, worth a combined $5.87B — down 26% from $7.92B a quarter earlier.
Sellers outnumbered buyers: 54 funds closed out of BLUE and 24 opened new positions — a net loss of 30 holders — while 78 trimmed existing stakes and 81 added.
The largest buyer was Sands Capital Management, adding an estimated $126M. The largest seller was Baillie Gifford & Co, cutting an estimated $90.5M.
- 241 institutional investors held bluebird bio (BLUE) as of Q3 2019, down from 273 in Q2 2019.
- Funds reported $5.87B of bluebird bio stock for Q3 2019, down 26% quarter-over-quarter.
- 24 funds opened new bluebird bio positions in Q3 2019 and 54 closed out, a net change of -30 holders.
- The largest bluebird bio buyer in Q3 2019 was Sands Capital Management, an estimated $126M added.
- The largest bluebird bio seller in Q3 2019 was Baillie Gifford & Co, an estimated $90.5M sold.
Based on aggregated 13F filings for Q3 2019.